ATE540116T1 - Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen - Google Patents
Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionenInfo
- Publication number
- ATE540116T1 ATE540116T1 AT05825667T AT05825667T ATE540116T1 AT E540116 T1 ATE540116 T1 AT E540116T1 AT 05825667 T AT05825667 T AT 05825667T AT 05825667 T AT05825667 T AT 05825667T AT E540116 T1 ATE540116 T1 AT E540116T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- start site
- aug start
- site region
- virus
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000000692 anti-sense effect Effects 0.000 title abstract 3
- 230000000840 anti-viral effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000007136 Filoviridae Infections Diseases 0.000 title 1
- 241001115402 Ebolavirus Species 0.000 abstract 3
- 241001115401 Marburgvirus Species 0.000 abstract 3
- 101150010086 VP24 gene Proteins 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 abstract 1
- 241000711950 Filoviridae Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710163270 Nuclease Proteins 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 241000288906 Primates Species 0.000 abstract 1
- 101150077651 VP35 gene Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 230000017066 negative regulation of growth Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62427704P | 2004-11-01 | 2004-11-01 | |
| US67169405P | 2005-04-14 | 2005-04-14 | |
| US11/264,444 US7524829B2 (en) | 2004-11-01 | 2005-10-31 | Antisense antiviral compounds and methods for treating a filovirus infection |
| PCT/US2005/039607 WO2006050414A2 (en) | 2004-11-01 | 2005-11-01 | Antisense antiviral compounds and methods for treating filovirus infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540116T1 true ATE540116T1 (de) | 2012-01-15 |
Family
ID=36319793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05825667T ATE540116T1 (de) | 2004-11-01 | 2005-11-01 | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US7524829B2 (de) |
| EP (1) | EP1814596B1 (de) |
| AT (1) | ATE540116T1 (de) |
| AU (1) | AU2005302155B2 (de) |
| CA (1) | CA2584873C (de) |
| WO (1) | WO2006050414A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004235396B2 (en) * | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| AU2005327188C9 (en) * | 2004-07-02 | 2011-09-22 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) * | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US7834064B2 (en) * | 2005-01-03 | 2010-11-16 | Andres Mario Salazar | Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
| WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| AU2006287530A1 (en) * | 2005-09-08 | 2007-03-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US7838658B2 (en) * | 2005-10-20 | 2010-11-23 | Ian Maclachlan | siRNA silencing of filovirus gene expression |
| WO2007092607A2 (en) * | 2006-02-09 | 2007-08-16 | Genetech, Inc. | Treatment of hemorrhagic viral infections using a tissue factor inhibitor |
| AU2013202322B2 (en) * | 2006-05-10 | 2016-04-28 | Avi Biopharma, Inc. | Oligonucleotide analogs having cationic intersubunit linkages |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| JP5350360B2 (ja) | 2007-03-29 | 2013-11-27 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | エボラ由来の遺伝子の発現を阻害するための組成物および方法 |
| WO2008156853A2 (en) * | 2007-06-20 | 2008-12-24 | The Board Of Regents Of The University Of Texas System | Inhibition of filovirus entry into cells and uses thereof |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| CA2710013A1 (en) * | 2007-12-28 | 2009-07-09 | Avi Biopharma, Inc. | Immunomodulatory agents and methods of use |
| ES2579628T3 (es) | 2009-02-23 | 2016-08-12 | Emergent Virology Llc | Iminoazúcares y métodos de tratamiento de enfermedades virales |
| EP2400843B1 (de) * | 2009-02-24 | 2015-11-11 | United Therapeutics Corporation | Iminozucker und verfahren zur behandlung von arenaviridae-erkrankungen |
| WO2010144759A1 (en) * | 2009-06-12 | 2010-12-16 | United Therapeutics Corporation | Iminosugars and methods of treating bunyaviral and togaviral diseases |
| WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
| US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| JP5575246B2 (ja) * | 2009-09-04 | 2014-08-20 | ユナイテッド セラピューティクス コーポレイション | ポックスウイルス感染の治療方法 |
| CN102595895A (zh) * | 2009-09-04 | 2012-07-18 | 联合治疗公司 | 亚氨基糖以及治疗丝状病毒性疾病的方法 |
| EP2473482B1 (de) * | 2009-09-04 | 2014-03-05 | United Therapeutics Corporation | Verfahren zur behandlung von orthomyxovirusinfektionen |
| AU2010319314C1 (en) | 2009-11-13 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| AU2011367230B2 (en) | 2011-05-05 | 2017-08-10 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| EP2722047A1 (de) | 2012-10-19 | 2014-04-23 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | 2,3-Dihydroquinazolin-4(1H)-one Derivate zur Verwendung in der Behandlung von viralen Infektionen |
| US9845469B2 (en) * | 2014-02-10 | 2017-12-19 | Ohio State Innovation Foundation | Antisense oligonucleotides for treatment of spinal muscular atrophy |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| WO2019104294A1 (en) * | 2017-11-27 | 2019-05-31 | Western University Of Health Sciences | Fluorophore-labeled phosphorodiamidate morpholino oligonucleotides and uses thereof |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5749847A (en) | 1988-01-21 | 1998-05-12 | Massachusetts Institute Of Technology | Delivery of nucleotides into organisms by electroporation |
| US5852188A (en) * | 1990-01-11 | 1998-12-22 | Isis Pharmaceuticals, Inc. | Oligonucleotides having chiral phosphorus linkages |
| JPH06501843A (ja) * | 1990-08-14 | 1994-03-03 | アイシス・ファーマシューティカルス・インコーポレーテッド | アンチセンスオリゴヌクレオチドによるインフルエンザａ型ウイルス，アン・アーバｈ２ｎ２株の阻害 |
| US6006174A (en) * | 1990-10-03 | 1999-12-21 | Interdigital Technology Coporation | Multiple impulse excitation speech encoder and decoder |
| US5495006A (en) | 1991-09-27 | 1996-02-27 | Allelix Biopharmaceuticals, Inc. | Antiviral polynucleotide conjugates |
| US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
| CA2125269A1 (en) | 1991-12-23 | 1993-07-08 | Chiron Diagnostics Corporation | Hav probes for use in solution phase sandwich hybridization assays |
| US20030171311A1 (en) | 1998-04-27 | 2003-09-11 | Lawrence Blatt | Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection |
| US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
| US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
| DE69434931T2 (de) | 1993-04-02 | 2007-11-22 | Rigel Pharmaceuticals, Inc., South San Francisco | Methode zur selektiven inaktivierung der viralen replication |
| US6824976B1 (en) | 1993-04-02 | 2004-11-30 | Rigel Pharmaceuticals, Inc. | Method for selective inactivation of viral replication |
| US5698695A (en) * | 1993-09-10 | 1997-12-16 | E. I. Du Pont De Nemours And Company | Process for preparing 2-amino-4,6-dichloropyrimidine |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6060456A (en) * | 1993-11-16 | 2000-05-09 | Genta Incorporated | Chimeric oligonucleoside compounds |
| US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US5989904A (en) | 1994-10-11 | 1999-11-23 | The Regents Of The University Of California | Selective inhibition of internally initiated RNA translation |
| GB9510718D0 (en) | 1995-05-26 | 1995-07-19 | Sod Conseils Rech Applic | Antisense oligonucleotides |
| US5955318A (en) | 1995-08-14 | 1999-09-21 | Abbott Laboratories | Reagents and methods useful for controlling the translation of hepatitis GBV proteins |
| US6214555B1 (en) | 1996-05-01 | 2001-04-10 | Visible Genetics Inc. | Method compositions and kit for detection |
| AU4425397A (en) | 1996-09-18 | 1998-04-14 | Vanderbilt University | Antisense gene therapy for rna viruses |
| ES2210761T3 (es) | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6228579B1 (en) * | 1997-11-14 | 2001-05-08 | San Diego State University Foundation | Method for identifying microbial proliferation genes |
| US6258570B1 (en) | 1998-04-17 | 2001-07-10 | University Of Pittsburgh | PCR assay for bacterial and viral meningitis |
| US6517842B1 (en) * | 1998-06-29 | 2003-02-11 | The United States Of America As Represented By The Secretary Of The Army | Marburg virus vaccines |
| AU771579B2 (en) | 1998-10-26 | 2004-03-25 | Avi Biopharma, Inc. | p53 antisense agent and method |
| US7094765B1 (en) * | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
| KR20010102992A (ko) * | 1999-01-29 | 2001-11-17 | 추후보정 | 표적 ｒｎａ를 검출하는 비-침입적 방법 |
| US6875747B1 (en) | 1999-05-24 | 2005-04-05 | Avi Bio Pharma, Inc. | Antisense to c-myc for treatment of polycystic kidney disease |
| US6669951B2 (en) | 1999-08-24 | 2003-12-30 | Cellgate, Inc. | Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| AU7473500A (en) | 1999-09-01 | 2001-03-26 | University Of Pittsburgh | Identification of peptides that facilitate uptake and cytoplasmic and/or nucleartransport of proteins, dna and viruses |
| US6521438B1 (en) | 1999-11-05 | 2003-02-18 | North Carolina State University | Chemoreceptors in plant parasitic nematodes |
| US20030095953A1 (en) | 1999-11-12 | 2003-05-22 | Myles C. Cabot | Methods of reversing drug resistance in cancer cells |
| DE29920656U1 (de) * | 1999-11-24 | 2000-02-17 | Vincent, Irvin G., Luxemburg, Wis. | Universelles Bauelement |
| EP1238071B1 (de) * | 1999-11-29 | 2008-04-23 | Avi Biopharma, Inc. | Gegen bakterielle 16s und 23s rrnas gerichtete ungeladene antisense oligonukleotide und deren verwendungen |
| WO2001049775A2 (en) * | 2000-01-04 | 2001-07-12 | Avi Biopharma, Inc. | Antisense antibacterial cell division composition and method |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
| SG144729A1 (en) | 2000-07-06 | 2008-08-28 | Bio Merieux | Method for controlling the microbiological quality of an aqueous medium and kit therefor |
| EP1301525B1 (de) * | 2000-07-06 | 2015-09-02 | Sarepta Therapeutics, Inc. | Transformation einer stammzellen enthaltenden, mit einem den wachstumsfaktor beta (tgf-beta) blockierenden mittel behandelten zusammensetzung und entsprechendes verfahren dazu |
| US6673917B1 (en) | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
| WO2002068637A2 (en) | 2000-10-20 | 2002-09-06 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-based treatment of diseases or conditions related to west nile virus infection |
| FR2819523B1 (fr) * | 2001-01-18 | 2003-06-13 | Jean Lemonnier | Boite sterile pour la culture de micro-organismes, ensemble et distributeur de boites |
| ATE335515T1 (de) | 2001-03-30 | 2006-09-15 | Univ Massachusetts | Morpholinobildgebung und therapie |
| US6828105B2 (en) * | 2001-10-16 | 2004-12-07 | Avi Biopharma, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| US6828579B2 (en) * | 2001-12-12 | 2004-12-07 | Hi-Z Technology, Inc. | Thermoelectric device with Si/SiC superlattice N-legs |
| US6841675B1 (en) | 2002-06-13 | 2005-01-11 | The Regents Of The University Of California | Piperazine-based nucleic acid analogs |
| EA008940B1 (ru) | 2002-09-13 | 2007-10-26 | Репликор, Инк. | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей |
| AU2003298605B2 (en) | 2002-10-16 | 2007-10-18 | Gen-Probe Incorporated | Compositions and methods for detecting west nile virus |
| EP1585755B1 (de) | 2002-12-31 | 2015-08-05 | Sigma-Aldrich Co. LLC | Verfahren und zusammenstellungen für die tandem-synthese von zwei oder mehr oligonukleotiden auf einen festen träger |
| KR101032853B1 (ko) | 2003-08-05 | 2011-05-06 | 에이브이아이 바이오파마 인코포레이티드 | 웨스트 나일 바이러스 감염을 치료하기 위한 약학적 조성물 |
| WO2005013905A2 (en) | 2003-08-07 | 2005-02-17 | Avi Biopharma, Inc. | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| WO2007030691A2 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| AU2006287530A1 (en) | 2005-09-08 | 2007-03-15 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| LT2735568T (lt) | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US8785407B2 (en) | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
-
2005
- 2005-10-31 US US11/264,444 patent/US7524829B2/en not_active Expired - Lifetime
- 2005-11-01 AT AT05825667T patent/ATE540116T1/de active
- 2005-11-01 EP EP05825667A patent/EP1814596B1/de not_active Expired - Lifetime
- 2005-11-01 CA CA2584873A patent/CA2584873C/en not_active Expired - Fee Related
- 2005-11-01 WO PCT/US2005/039607 patent/WO2006050414A2/en not_active Ceased
- 2005-11-01 AU AU2005302155A patent/AU2005302155B2/en not_active Ceased
-
2006
- 2006-05-11 US US11/433,840 patent/US7507196B2/en not_active Expired - Lifetime
-
2009
- 2009-03-11 US US12/402,461 patent/US8030292B2/en active Active
- 2009-03-11 US US12/402,464 patent/US8168604B2/en active Active
- 2009-03-11 US US12/402,455 patent/US8030291B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186849A1 (en) | 2009-07-23 |
| US8168604B2 (en) | 2012-05-01 |
| US8030292B2 (en) | 2011-10-04 |
| AU2005302155A1 (en) | 2006-05-11 |
| US8030291B2 (en) | 2011-10-04 |
| CA2584873A1 (en) | 2006-05-11 |
| US20060205693A1 (en) | 2006-09-14 |
| US20060281701A1 (en) | 2006-12-14 |
| US7507196B2 (en) | 2009-03-24 |
| EP1814596A2 (de) | 2007-08-08 |
| WO2006050414A2 (en) | 2006-05-11 |
| EP1814596A4 (de) | 2010-06-16 |
| US7524829B2 (en) | 2009-04-28 |
| EP1814596B1 (de) | 2012-01-04 |
| US20090186848A1 (en) | 2009-07-23 |
| CA2584873C (en) | 2017-04-18 |
| US20090186847A1 (en) | 2009-07-23 |
| AU2005302155B2 (en) | 2012-09-06 |
| WO2006050414A3 (en) | 2007-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1814596A4 (de) | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen | |
| WO2006047683A3 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
| DE602007006457D1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| EP1507791A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| PH12021551007A1 (en) | S-antigen transport inhibiting oligonucleotide polymers and methods | |
| EP1937278A4 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von picornavirus-infektion | |
| DK1692265T3 (da) | Fremgangsmåde til hindring af en virus-celle-fusion ved hæmning af fusionsinitieringsområdets funktion i RNA-vira med klasse 1-membranfusogene envelopeproteiner | |
| EP1802777A4 (de) | Antivirale antisense-verbindung und verfahren zur behandlung einer ssrna-virusinfektion | |
| WO2007030691A3 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| EP1623012A4 (de) | Antisense-antivirusmittel und verfahren zur behandlung einer ssrna-virusinfektion | |
| ATE478082T1 (de) | Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen | |
| ATE552347T1 (de) | Oligonukleotidverbindung und verfahren zur behandlung von nidovirusinfektionen | |
| DE602004030583D1 (de) | Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| WO2005013905A3 (en) | SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION | |
| EP2092078A4 (de) | Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer | |
| EA200401362A1 (ru) | Антивирусная терапия, основанная на противодействии рнк | |
| EP2325314A3 (de) | Targeting von Zwischenprodukten zur Gegenstrangreplikation von einzelstrangigen Viren durch RNAi | |
| PH12022553394A1 (en) | Conjugate of double-stranded sirna analogue | |
| RU2008117439A (ru) | Аптамеры, содержащие модифицированные арабинозой нуклеотиды | |
| AU2013205445B2 (en) | Antisense antiviral compound and method for treating picornavirus infection | |
| EA200301089A1 (ru) | Противовирусный агент |